Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.46 |
| ▸ | HTR2B | P41595 | 4/20 | 0.46 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5742260 | 1.00 | HTR2C (0.46) | HTR2CHTR2BNOS3NOS1NOS2 | |
| SCHEMBL4491187 | 0.92 | HRH3 (0.44) | HTR2CHTR2BHTR1DHTR1BOPRM1 | |
| SCHEMBL30962640 | 0.88 | HTR2C (0.49) | HTR2CHTR2BNOS3NOS1NOS2 | |
| SCHEMBL30962765 | 0.88 | HTR2C (0.49) | HTR2CHTR2BNOS3NOS1NOS2 | |
| SCHEMBL31203041 | 0.88 | HTR2C (0.49) | HTR2CHTR2BNOS3NOS1NOS2 | |
| SCHEMBL6821190 | 0.84 | UTS2R (0.44) | HTR2CHTR2BNOS3NOS1NOS2 | |
| SCHEMBL6821193 | 0.84 | UTS2R (0.44) | HTR2CHTR2BNOS3NOS1NOS2 | |
| SCHEMBL5835364 | 0.84 | UTS2R (0.52) | HTR2CHTR2BSLC6A4HTR6 | |
| SCHEMBL5743838 | 0.84 | UTS2R (0.52) | HTR2CHTR2BSLC6A4HTR6 | |
| SCHEMBL7031279 | 0.84 | PIK3CD (0.48) | HTR2CHTR2BNOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1385840-B1 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2006-10-04 | — | — | EP | claimed |
| US-7091204-B2 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-15 | — | — | US | claimed |
| US-20040152891-A1 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION | 2004-08-05 | — | — | US | claimed |
| EP-1385840-B1 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2006-10-04 | — | — | EP | disclosed |
| US-7091204-B2 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-15 | — | — | US | disclosed |
| US-20040152891-A1 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152891-A1 | Sulfonamides | UTS2R, PRSS2, STS | HTR2C 1439/4885HTR2B 1119/4885NOS3 3459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.